Related Experiment Video

Updated: May 30, 2026

Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment
08:49

Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment

Published on: August 2, 2024

Natriuretic Peptide-guided therapy for heart failure

Robert J Mentz1, G Michael Felker

  • 1Department of Cardiology, Duke Clinical Research Institute, Durham, NC, USA.

Circulation Journal : Official Journal of the Japanese Circulation Society
|July 28, 2011
PubMed

Insights

Biomarker-guided therapy (BGT) for chronic heart failure (HF) shows mixed results. Standardized algorithms and endpoints are needed to interpret BGT

Area of Science:

  • Cardiology
  • Internal Medicine
  • Biomedical Research

Background:

  • Chronic heart failure (HF) presents a significant global health challenge with increasing prevalence and costs.
  • Current HF management strategies often result in suboptimal patient outcomes.
  • Evidence-based medication underutilization is a key issue in HF treatment.

Purpose of the Study:

  • To review the rationale and accumulated data for biomarker-guided therapy (BGT) in chronic HF.
  • To explore the complexities and unanswered questions surrounding BGT in HF management.
  • To address the need for standardized approaches in BGT for heart failure.

Main Methods:

  • Review of recent clinical trials investigating BGT in chronic HF.
  • Analysis of data regarding the efficacy and outcomes of BGT.
  • Examination of factors contributing to the heterogeneity of trial results.

Main Results:

  • Recent trials of BGT in chronic HF have yielded inconsistent results, with some showing benefits and others none.
  • Heterogeneity in patient populations complicates the interpretation of BGT trial outcomes.
  • Lack of standardized BGT algorithms and trial endpoints hinders consistent findings.

Conclusions:

  • Biomarker-guided therapy (BGT) holds potential for improving chronic heart failure (HF) management.
  • Further research is required to establish standardized BGT algorithms and trial endpoints.
  • Clarifying the role of BGT is crucial for optimizing HF treatment strategies and patient outcomes.

More Related Videos

Isolation of Atrial Myocytes from Adult Mice08:34

Isolation of Atrial Myocytes from Adult Mice

Published on: July 25, 2019

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...